Cassiopea selects DATATRAK platform for significant global study

DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified dClinical^™ technologies and delivering related services for the clinical trials industry, today announced that Cassiopea S.p.A., the newly IPO'd former subsidiary of longtime partner Cosmo Pharmaceuticals SA has selected DATATRAK for a significant global study.

"Technology should support clinical research, not complicate it," said Laurence P. Birch, Chairman and CEO, DATATRAK. "As long time DATATRAK users, Cosmo Pharmaceuticals knows firsthand that we simplify clinical research. We look forward to supporting the vital research of Cassiopeia and delivering an exceptional customer experience," concluded Birch.

"Success in clinical research requires software that lets us focus on the trial. It must be easy to use, protect patients, and provide insight on demand. DATATRAK delivers technology that supports our work without adding complicated processes," said Louise Dube, Director of R&D of Cassiopea S.p.A.

SOURCE DATATRAK International, Inc.